PMID- 31768625
OWN - NLM
STAT- MEDLINE
DCOM- 20200330
LR  - 20220218
IS  - 1432-2307 (Electronic)
IS  - 0945-6317 (Print)
IS  - 0945-6317 (Linking)
VI  - 476
IP  - 3
DP  - 2020 Mar
TI  - Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma.
PG  - 455-463
LID - 10.1007/s00428-019-02684-9 [doi]
AB  - Osteoid osteoma and osteoblastoma are bone-forming tumors shown to harbor FOS 
      (87%) and FOSB (3%) rearrangements. The aim was to evaluate the 
      immunohistochemical expression of FOS and FOSB in these tumors in comparison to 
      other bone tumors, to evaluate the influence of decalcification, and to correlate 
      immunohistochemical findings with the underlying genetic alteration using 
      fluorescence in situ hybridization (FISH). Immunohistochemistry using whole 
      sections was performed on osteoid osteoma (n=23), osteoblastoma (n=22), 
      osteoblastoma-like osteosarcoma (n=3), reactive (n=3), and proliferative (n=11) 
      bone lesions. Immunoreactivity in giant cell tumor of bone (n=74), aneurysmal 
      bone cyst (n=6), chondromyxoid fibroma (n=20), osteosarcoma (n=85), 
      chondroblastoma (n=17), and clear cell chondrosarcoma (n=20) was assessed using 
      tissue micro arrays. Strong nuclear expression of FOS in > 50% of the tumor cells 
      was observed in all osteoid osteomas (22/22), in 57% of osteoblastomas (12/21) 
      and in 3/197 control cases. FOS immunoreactivity disappeared after > 3 days 
      decalcification. FOS rearrangements were present in 94% of osteoid osteomas and 
      osteoblastomas, with a concordance of 86% between FISH and immunohistochemistry. 
      Two osteoblastomas (5%) were positive for FOSB, as opposed to 8/177 control 
      cases. Additional FISH revealed no FOSB rearrangements in these cases. To 
      conclude, in short decalcified biopsies, FOS immunohistochemistry can be used to 
      diagnose osteoid osteoma and osteoblastoma, as overexpression is seen in the 
      majority, being rare in their mimics. FOS immunohistochemistry should not be used 
      after long decalcification. Moreover, low level of focal expression found in 
      other lesions and tissues might cause diagnostic problems, in which case FISH 
      could be employed.
FAU - Lam, Suk Wai
AU  - Lam SW
AD  - Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333, 
      ZA, Leiden, The Netherlands.
FAU - Cleven, Arjen H G
AU  - Cleven AHG
AD  - Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333, 
      ZA, Leiden, The Netherlands.
FAU - Kroon, Herman M
AU  - Kroon HM
AD  - Department of Radiology, Leiden University Medical Center, Albinusdreef 2, 2333, 
      ZA, Leiden, The Netherlands.
FAU - Briaire-de Bruijn, Inge H
AU  - Briaire-de Bruijn IH
AD  - Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333, 
      ZA, Leiden, The Netherlands.
FAU - Szuhai, Karoly
AU  - Szuhai K
AD  - Department of Cell and Chemical Biology, Leiden University Medical Center, 
      Einthovenweg 20, 2333, ZC, Leiden, The Netherlands.
FAU - Bovee, Judith V M G
AU  - Bovee JVMG
AUID- ORCID: 0000-0003-1155-0481
AD  - Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333, 
      ZA, Leiden, The Netherlands. j.v.m.g.bovee@lumc.nl.
LA  - eng
PT  - Journal Article
DEP - 20191125
PL  - Germany
TA  - Virchows Arch
JT  - Virchows Archiv : an international journal of pathology
JID - 9423843
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (FOS protein, human)
RN  - 0 (FOSB protein, human)
RN  - 0 (Proto-Oncogene Proteins c-fos)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Biomarkers, Tumor/*analysis
MH  - Bone Neoplasms/*diagnosis
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoblastoma/*diagnosis
MH  - Osteoma, Osteoid/*diagnosis
MH  - Proto-Oncogene Proteins c-fos/*analysis/biosynthesis
MH  - Young Adult
PMC - PMC7085481
OTO - NOTNLM
OT  - Bone tumors
OT  - FOS
OT  - Fluorescence in situ hybridization
OT  - Immunohistochemistry
OT  - Osteoblastoma
OT  - Osteoid osteoma
EDAT- 2019/11/27 06:00
MHDA- 2020/03/31 06:00
PMCR- 2019/11/25
CRDT- 2019/11/27 06:00
PHST- 2019/08/01 00:00 [received]
PHST- 2019/09/30 00:00 [accepted]
PHST- 2019/09/24 00:00 [revised]
PHST- 2019/11/27 06:00 [pubmed]
PHST- 2020/03/31 06:00 [medline]
PHST- 2019/11/27 06:00 [entrez]
PHST- 2019/11/25 00:00 [pmc-release]
AID - 10.1007/s00428-019-02684-9 [pii]
AID - 2684 [pii]
AID - 10.1007/s00428-019-02684-9 [doi]
PST - ppublish
SO  - Virchows Arch. 2020 Mar;476(3):455-463. doi: 10.1007/s00428-019-02684-9. Epub 
      2019 Nov 25.